12/11
05:57 am
aclx
ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma [Yahoo! Finance]
Low
Report
ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma [Yahoo! Finance]
12/10
01:30 pm
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at UBS Group AG from $106.00 to $114.00. They now have a "buy" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at UBS Group AG from $106.00 to $114.00. They now have a "buy" rating on the stock.
12/10
08:00 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
12/9
08:11 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.
Medium
Report
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.
12/8
11:02 pm
aclx
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition [Yahoo! Finance]
Low
Report
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition [Yahoo! Finance]
12/8
11:00 pm
aclx
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
Low
Report
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
12/5
07:55 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
11/13
01:26 pm
aclx
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice [Yahoo! Finance]
Medium
Report
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice [Yahoo! Finance]
11/12
12:36 pm
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Truist Financial Co. from $87.00 to $136.00. They now have a "buy" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Truist Financial Co. from $87.00 to $136.00. They now have a "buy" rating on the stock.
11/8
10:59 am
aclx
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Low
Report
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
11/7
06:40 pm
aclx
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Medium
Report
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/7
04:00 pm
aclx
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
Medium
Report
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
11/6
08:07 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at HC Wainwright from $80.00 to $95.00. They now have a "buy" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at HC Wainwright from $80.00 to $95.00. They now have a "buy" rating on the stock.
11/6
08:07 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $96.00 price target on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $96.00 price target on the stock.
11/6
08:07 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Robert W. Baird from $77.00 to $106.00. They now have an "outperform" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Robert W. Baird from $77.00 to $106.00. They now have an "outperform" rating on the stock.
11/6
08:07 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Bank of America Co. from $84.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Bank of America Co. from $84.00 to $100.00. They now have a "buy" rating on the stock.
11/6
08:06 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Morgan Stanley from $81.00 to $106.00. They now have an "overweight" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Morgan Stanley from $81.00 to $106.00. They now have an "overweight" rating on the stock.
11/5
09:18 am
aclx
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World [Yahoo! Finance]
Low
Report
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World [Yahoo! Finance]
11/5
09:00 am
aclx
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
Medium
Report
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
10/31
10:58 pm
aclx
Arcellx (ACLX) Surged in Q3. Here's Why [Yahoo! Finance]
Low
Report
Arcellx (ACLX) Surged in Q3. Here's Why [Yahoo! Finance]
10/31
08:35 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $96.00 price target on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $96.00 price target on the stock.
10/18
03:33 pm
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC.
10/18
10:57 am
aclx
Baron Health Care Fund Q3 2024 Shareholder Letter [Seeking Alpha]
Low
Report
Baron Health Care Fund Q3 2024 Shareholder Letter [Seeking Alpha]
10/18
10:35 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Stifel Nicolaus from $83.00 to $122.00. They now have a "buy" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Stifel Nicolaus from $83.00 to $122.00. They now have a "buy" rating on the stock.
10/17
09:38 am
aclx
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $85.00 to $115.00. They now have a "buy" rating on the stock.
Low
Report
Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $85.00 to $115.00. They now have a "buy" rating on the stock.